Psychiatric assessment prior to and after switch from levetiracetam to brivaracetam

Over the last decades, more than 15 antiseizure medications (ASMs) have been introduced to the market, which are referred to as “new” or “newer” ASMs, as opposed to the older ones [1]. Some of the newer ASMs have benefits in terms of tolerability and interactions with other drugs [1] but they can also cause side effects, including psychiatric, cognitive, and behavioral adverse events. Levetiracetam (LEV) is one of the most commonly used new ASMs worldwide due to its beneficial profile in terms of ease of use, virtual non-existence of interactions, good efficacy, and tolerability [2].

0